(Q26786687)

inferred from title

author

Christopher M O'Connor

10

Christopher M O'Connor

0 references

Gary Felker

1

G Michael Felker

0 references

Robert J. Mentz

2

Robert J Mentz

0 references

Marvin A. Konstam

12

Marvin A Konstam

0 references

Kirkwood F Adams

3

Kirkwood F Adams

0 references

Chetan Kantibhai Patel

6

Chetan B Patel

0 references

Gregory F Egnaczyk

5

Gregory F Egnaczyk

0 references

Patricia Wedge

9

Patricia Wedge

0 references

James E Udelson

11

James E Udelson

0 references

author name string

Robert T Cole

4

0 references

Mona Fiuzat

7

0 references

Douglas Gregory

Circulation: Heart Failure

8

0 references

language of work or name

English

0 references

publication date

September 2015

0 references

published in

1 reference

Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial

PubMed

volume

8

0 references

page(s)

997-1005

0 references

issue

5

0 references

cites work

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Decongestion in acute heart failure

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Furosemide and the progression of left ventricular dysfunction in experimental heart failure

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Vasopressin antagonism in heart failure

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Combination of loop diuretics with thiazide-type diuretics in heart failure

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Diuretics and ultrafiltration in acute decompensated heart failure.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Diuretic strategies in patients with acute decompensated heart failure

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Ultrafiltration in decompensated heart failure with cardiorenal syndrome

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Effects of tolvaptan on dyspnoea relief from the EVEREST trials

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Diuretic response in acute heart failure: clinical characteristics and prognostic significance.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Acute heart failure syndromes: current state and framework for future research

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021

Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCHEARTFAILURE.115.002259

7 January 2021